This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 6, 2003
Last updated: July 17, 2013
Last verified: July 2004

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining rituximab with interleukin-2 in treating patients who have relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.

Condition Intervention Phase
Lymphoma Biological: aldesleukin Biological: rituximab Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Labeled, Phase II Study of Rituximab in Combination With Recombinant IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate- or High-Grade Histology

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: January 2003
Study Completion Date: June 2004
Detailed Description:


  • Determine the clinical efficacy of rituximab and interleukin-2 in patients with relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.
  • Determine the 2-year progression-free survival of patients treated with this regimen.
  • Determine the safety of this regimen in these patients.
  • Correlate response with natural killer cell numbers and rituximab, interleukin-2 (IL-2), and soluble IL-2 receptor levels in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study.

Patients receive rituximab IV once weekly on weeks 1-4 and interleukin-2 subcutaneously 3 times weekly on weeks 2-9. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 12 weeks for 2 years.

PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of intermediate- or high-grade non-Hodgkin's lymphoma according to the Working Formulation, including the following subtypes:

    • Diffuse large cell lymphoma
    • Diffuse mixed cell lymphoma
    • Immunoblastic large cell lymphoma
  • CD20+ disease
  • Measurable progressive or refractory disease
  • No primary CNS lymphoma or lymphomatous meningitis NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Lymphocyte count less than 20,000/mm^3
  • Absolute neutrophil count at least 1,000/mm^3
  • Platelet count at least 75,000/mm^3
  • Hemoglobin at least 9.5 g/dL


  • SGOT and SGPT no greater than 1.5 times upper limit of normal
  • Bilirubin normal
  • No liver disease
  • Hepatitis C-seropositive patients are allowed provided they have no active disease, as demonstrated by any of the following:

    • Undetectable hepatitis C viral loads
    • Biopsy showing no active disease
    • Normal transaminases on at least 3 different occasions within the past year


  • Creatinine normal


  • No clinically significant cardiac dysfunction
  • No myocardial infarction within the past 6 months
  • No heart failure within the past 6 months


  • No clinically significant pulmonary dysfunction
  • Patients with prior radiotherapy to the lung or autologous transplantation must have FEV greater than 50% and DLCO greater than 50% within 8 weeks before study treatment


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No significant infections within the past 2 weeks (including pneumonia or bronchitis)
  • No history of autoimmune disease
  • No prior or concurrent malignancy except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, or other solid tumor curatively treated with no evidence of recurrence within the past 2 years
  • No symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism
  • No prior type 1 hypersensitivity or anaphylactic reactions to murine products, rituximab, or radioimmunoconjugated anti-CD20 antibody infusion


Biologic therapy

  • At least 3 months since prior autologous bone marrow transplantation
  • No prior allogeneic bone marrow transplantation
  • No prior interleukin-2
  • No prior interferon (alfa, beta, or gamma)
  • No concurrent basiliximab, daclizumab, or monoclonal antibody OKT3


  • More than 30 days since prior chemotherapy
  • No concurrent anticancer chemotherapy

Endocrine therapy

  • More than 2 weeks since prior systemic steroids
  • No concurrent systemic corticosteroids


  • More than 30 days since prior radiotherapy
  • No concurrent radiotherapy


  • More than 30 days since prior major surgery


  • More than 30 days since other prior investigational drugs
  • More than 30 days since prior immunosuppressive medications
  • No concurrent immunosuppressive medications including the following:

    • Cyclosporine
    • Mycophenolate mofetil
    • Tacrolimus
    • Sirolimus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00059904

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Tarun Kewalramani, MD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00059904     History of Changes
Other Study ID Numbers: CHIR-IL2005-A01
CDR0000298986 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: May 6, 2003
Last Updated: July 17, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult immunoblastic large cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on August 17, 2017